Korea 2019 Review: Industry Spooked By Invossa Affair, Disappointing Trials But Hopes Intact

The South Korean pharma/biotech industry suffered a series of negative blows in 2019 but there were still notable achievements including major drug approvals and large-scale licensing deals.

Scrip Perspectives 2019 to 2020
Despite Challenges, Some Major Achievements In Korea In 2019

More from South Korea

More from Focus On Asia